Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix (Belatacept)-Based Immunosuppression
Latest Information Update: 20 Feb 2023
At a glance
- Drugs Belatacept (Primary) ; Ciclosporin; Tacrolimus
- Indications Renal transplant rejection
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 03 Jun 2020 Results presented at the 2020 American Transplant Congress
- 20 Feb 2020 Status changed from active, no longer recruiting to completed.
- 12 Feb 2020 This trial has been completed in Germany, according to Eudra record.